Literature DB >> 11483331

Definitions of biochemical failure in prostate cancer following radiation therapy.

J M Taylor1, K A Griffith, H M Sandler.   

Abstract

PURPOSE: The American Society for Therapeutic Radiology and Oncology (ASTRO) published a consensus panel definition of biochemical failure following radiation therapy for prostate cancer. In this paper, we develop a series of alternative definitions of biochemical failure. Using data from 688 patients, we evaluated the sensitivity and specificity of the various definitions, with respect to a defined "clinically meaningful" outcome. METHODS AND MATERIALS: The ASTRO definition of biochemical failure requires 3 consecutive rises in prostate-specific antigen (PSA). We considered several modifications to the standard definition: to require PSA rises of a certain magnitude, to consider 2 instead of 3 rises, to require the final PSA value to be greater than a fixed cutoff level, and to define biochemical failure based on the slope of PSA over 1, 1.5, or 2 years. A clinically meaningful failure is defined as local recurrence, distant metastases, initiation of unplanned hormonal therapy, unplanned radical prostatectomy, or a PSA > 25 later than 6 months after radiation.
RESULTS: Requiring the final PSA in a series of consecutive rises to be larger than 1.5 ng/mL increased the specificity of biochemical failure. For a fixed specificity, defining biochemical failure based on 2 consecutive rises, or the slope over the last year, could increase the sensitivity by up to approximately 20%, compared to the ASTRO definition. Using a rule based on the slope over the previous year or 2 rises leads to a slightly earlier detection of biochemical failure than does the ASTRO definition. Even with the best rule, only approximately 20% of true failures are biochemically detected more than 1 year before the clinically meaningful event time.
CONCLUSION: There is potential for improvement in the ASTRO consensus definition of biochemical failure. Further research is needed, in studies with long follow-up times, to evaluate the relationship between various definitions of biochemical failure and true clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483331     DOI: 10.1016/s0360-3016(01)01571-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  [Radical salvage prostatectomy : Treatment of local recurrence of prostate cancer after radiotherapy].

Authors:  A Heidenreich; R Semrau; D Thüer; D Pfister
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

2.  A stochastic model for PSA levels: behavior of solutions and population statistics.

Authors:  Pavel Belík; P W A Dayananda; John T Kemper; Mikhail M Shvartsman
Journal:  J Math Biol       Date:  2006-07-11       Impact factor: 2.259

Review 3.  [Locally recurrent prostate cancer following radiation therapy: radical salvage prostatectomy].

Authors:  A Heidenreich; D Thüer; D Pfister
Journal:  Urologe A       Date:  2010-06       Impact factor: 0.639

Review 4.  [Salvage radical prostatectomy].

Authors:  R E Hautmann
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

5.  Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.

Authors:  Michael E Ray; Kyounghwa Bae; Maha H A Hussain; Gerald E Hanks; William U Shipley; Howard M Sandler
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

Review 6.  Radiation for prostate cancer: use of biochemical failure as an endpoint following radiotherapy.

Authors:  Deborah A Kuban; Howard D Thames; Larry B Levy
Journal:  World J Urol       Date:  2003-08-16       Impact factor: 4.226

7.  [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].

Authors:  A Heidenreich; C Ohlmann; E Ozgür; U Engelmann
Journal:  Urologe A       Date:  2006-04       Impact factor: 0.639

8.  Saudi Oncology Society clinical management guidelines for prostate cancer.

Authors:  Ashraf J Abusamra; Shouki Bazarbashi; Yasser Bahader; Hussain Kushi; Danny Rabah; Dany Rabbah; Naser Al Bogami; Khalid Al Ghamdi; Abdullah Al Ghamdi; Khaled Balaraj; Raouf Seyam; Mohammed Al Otaibi; Eyad Al Saeed
Journal:  Urol Ann       Date:  2011-03

9.  Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Authors:  Sultan Alkhateeb; Ashraf Abusamra; Danny Rabah; Mohammed Alotaibi; Rana Mahmood; Mubarak Almansour; Esam Murshid; Abdullah Alsharm; Ashwaq Alolayan; Imran Ahmad; Hussain Alkushi; Abdullah Alghamdi; Shouki Bazarbashi
Journal:  Urol Ann       Date:  2014-10

Review 10.  Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Authors:  Ashraf Abusamra; Esam Murshid; Hussain Kushi; Sultan Alkhateeb; Mubarak Al-Mansour; Ahmad Saadeddin; Danny Rabah; Shouki Bazarbashi; Mohammed Alotaibi; Abdullah Alghamdi; Khalid Alghamdi; Abdullah Alsharm; Imran Ahmad
Journal:  Urol Ann       Date:  2016 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.